PHQ-2 Depression Screener (Patient Health Questionnaire-2)
2-item ultra-brief depression screener. Score ≥3 indicates need for full PHQ-9 evaluation.
PHQ-2 Screening Result Interpreter
Score ≥3 indicates a positive screen. Proceed to full PHQ-9 and clinical evaluation; ask directly about suicidal ideation. The PHQ-2 alone is not sufficient to diagnose depression.
2 items (depressed mood, anhedonia), each scored 0–3 based on frequency in the past 2 weeks. Total range 0–6. A single cutoff of ≥3 identifies a positive screen.
| Total score | Interpretation |
|---|---|
| 3+ | Positive screenScore ≥3 indicates a positive screen. Proceed to full PHQ-9 and clinical evaluation; ask directly about suicidal ideation. The PHQ-2 alone is not sufficient to diagnose depression. |
| 0–2 | Negative screenScore below 3 is a negative screen. The PHQ-2 has a high negative predictive value, though clinical judgment should guide further assessment when suspicion remains high. |
Kroenke K, Spitzer RL, Williams JBW. Med Care. 2003;41(11):1284–1292. Cutoff ≥3 identified as optimal screening threshold (sensitivity 83%, specificity 92% against structured clinical interview). Educational reference only — not a diagnostic tool.
The PHQ-2 is a 2-item depression screener derived from the PHQ-9. With a score range of 0–6 and a ≥3 positive threshold, it identifies patients who need the full PHQ-9 in under 1 minute.
What is the PHQ-2?
The PHQ-2 (Patient Health Questionnaire-2) consists of the first two questions of the PHQ-9, assessing the two core symptoms of major depressive disorder: anhedonia (loss of interest or pleasure) and depressed mood. Developed from the PRIME-MD diagnostic tool and validated by Kroenke et al. (2003), it is the recommended first-step depression screen in primary care, behavioural health integration, and population health programs.
Each item is rated 0–3 based on symptom frequency over the past 2 weeks (Not at all / Several days / More than half the days / Nearly every day), yielding a total score of 0–6. A score of 3 or higher is a positive screen and indicates the need for full PHQ-9 administration and clinical evaluation.
The PHQ-2 is part of the PHQ family of tools (PHQ-9, PHQ-A, PHQ-SADS) developed by Drs. Spitzer, Kroenke, and Williams. It is freely available in the public domain and widely endorsed by USPSTF, APA, and primary care guidelines internationally.
PHQ-2 is a Gateway Screen, Not a Standalone Diagnostic
A positive PHQ-2 (≥3) requires follow-up with the full PHQ-9 and clinical evaluation. The PHQ-2 alone is not sufficient to diagnose depression or determine severity. It is designed as an efficient first step to identify who needs further assessment.
Public Domain
The PHQ-2 is in the public domain. No permissions, licensing fees, or royalties are required for clinical, educational, or research use.
The Two PHQ-2 Questions
Both questions ask about the past 2 weeks. Each is rated on a 4-point scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), 3 (Nearly every day).
Over the past 2 weeks, how often have you been bothered by little interest or pleasure in doing things?
Depressed Mood
Over the past 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?
Administration Best Practices
- Administer at intake and as a periodic check at follow-up visits
- Proceed to PHQ-9 promptly when score ≥3, do not defer to a later visit
- Can be patient self-administered (paper, tablet, or digital), saving clinician time
- Always ask about suicidal ideation when PHQ-2 is positive, regardless of PHQ-9 results
Answer both questions based on how often you have been bothered over the past 2 weeks.
PHQ-2 Scoring & Interpretation
Sensitivity & Specificity
At the ≥3 threshold (Kroenke et al., 2003):
- Sensitivity: 76–83% for major depressive disorder (pooled ~76%, Levis et al. 2020 JAMA meta-analysis; original 2003 study: 83%)
- Specificity: 78–92% (varies by population)
- PPV: 54% in primary care populations
- NPV: 97%, excellent for ruling out depression
When PHQ-2 is Positive (≥3)
Required follow-up steps:
- Administer full PHQ-9 (9 items) for severity scoring
- Ask directly about suicidal ideation (PHQ-9 item 9)
- Conduct clinical interview to assess duration, impairment, and triggers
- Consider GAD-7 for comorbid anxiety (very common)
Negative PHQ-2 Doesn't Rule Out All Depression
The PHQ-2's NPV of 97% is excellent but not perfect. If clinical suspicion is high (e.g., patient reports sadness, sleep changes, or weight loss), administer the full PHQ-9 regardless of PHQ-2 score. Clinical judgment always supersedes a screening score.
PHQ-2 vs PHQ-9: When to Use Each
The PHQ-2 and PHQ-9 are designed to work together as a two-stage screening and assessment protocol.
Clinical Guidance: The PHQ-2 functions as a triage gate. In high-volume settings (primary care, urgent care, employee health), administer PHQ-2 to all patients. Those who screen positive (≥3) proceed directly to PHQ-9. This two-stage approach reduces patient burden for the ~80% who screen negative while ensuring the PHQ-9's full diagnostic power is applied where it matters. For measurement-based care programs focused on depression treatment monitoring, use PHQ-9 directly at every visit rather than starting with PHQ-2.
Documenting PHQ-2 scores in clinical notes?
PHQ-2 scores belong in the Objective section of your note. See our SOAP notes guide and Intake Notes guide for templates and examples.
Billing the PHQ-2 (CPT 96127)
PHQ-2 administration qualifies for reimbursement under CPT code 96127 (brief emotional/behavioural assessment). The AMA allows up to 4 units per encounter; Medicare limits this to 3 units per encounter. Each unit represents one validated scale administered, scored, and documented. When the PHQ-2 is positive and you escalate to the full PHQ-9, both scales can each be billed as a separate 96127 unit in the same encounter.
Frequently Asked Questions
What is a positive PHQ-2 score?
A PHQ-2 score of 3 or higher is considered a positive screen for depression. This cutoff was identified as the optimal threshold in the original 2003 validation study by Kroenke et al., with a sensitivity of 83% and a specificity of 92% against a structured clinical interview. A positive result indicates the need for full PHQ-9 administration and clinical evaluation.
Can the PHQ-2 diagnose depression?
No. The PHQ-2 is a screening tool, not a diagnostic instrument. A positive screen (≥3) identifies patients who need further evaluation with the full PHQ-9 and a clinical interview. Diagnosis of major depressive disorder requires a comprehensive clinical assessment that considers symptom duration, functional impairment, and differential diagnoses.
Is the PHQ-2 self-report or clinician-administered?
The PHQ-2 is designed as a patient self-report questionnaire. Patients complete it on paper, tablet, or a digital platform without requiring clinician prompting, which makes it practical for routine intake screening in high-volume settings. Scores are then reviewed and acted upon by a clinician.
How is the PHQ-2 scored?
Each of the two items is rated on a 4-point frequency scale: 0 (Not at all), 1 (Several days), 2 (More than half the days), and 3 (Nearly every day). The two item scores are summed for a total score ranging from 0 to 6. A total score of 3 or above is a positive screen.
References
- 1.Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284-1292.View source
- 2.Levis B, Sun Y, He C, et al.; Depression Screening Data (DEPRESSD) PHQ Collaboration. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. JAMA. 2020;323(22):2290-2300.View source
- 3.Levis B, Benedetti A, Thombs BD. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;365:l1476.View source
Bill this assessment
The PHQ-2 Depression Screener (Patient Health Questionnaire-2) qualifies for reimbursement under these CPT codes (US).
Last reviewed: Jun 3, 2026
Related Assessments
Explore complementary clinical tools and screeners